Arcadia Biosciences, Inc. 8-K

What Happened

• On May 14, 2026, Arcadia Biosciences, Inc. (RKDA) issued a press release announcing its financial results for the first quarter of 2026 and filed a Current Report on Form 8-K (Item 2.02) to furnish that information. The press release is attached as Exhibit 99.1 and the company’s financial information tables are attached as Exhibit 99.2.
• The Form 8-K was signed by CEO Thomas J. Schaefer. The filing also includes an Inline XBRL cover page (Exhibit 104).

Key Details

• Filing date: May 14, 2026 (8-K furnished under Item 2.02 — Results of Operations and Financial Condition).
• Exhibits furnished: 99.1 (press release) and 99.2 (financial information tables); 104 (interactive XBRL data).
• Legal note: The press release and financial tables were furnished, not “filed,” and thus are not subject to the liabilities of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act as stated in the 8-K.
• Signed by: Thomas J. Schaefer, Chief Executive Officer.

Why It Matters

• This 8-K signals Arcadia has publicly released its quarterly results — earnings, revenue, and other performance metrics should be in the attached press release and tables. Retail investors should review Exhibits 99.1 and 99.2 for the company’s reported quarterly results and any business highlights.
• Because the materials are furnished (not “filed”), they provide timely disclosure but carry different legal protections; for a fuller, filed accounting and management discussion you should watch for the company’s upcoming Form 10-Q or other subsequent filings on SEC EDGAR.